Hepatocellular carcinoma is the most common type of liver cancer in adults. Many patients who develop liver cancer have long-standing cirrhosis (scar tissue formation from liver cell damage), and early detection can be difficult because signs and symptoms often do not appear until later stages. It is estimated that approximately 40,710 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed (about 29,200 in men and 11,510 in women, and about 28,920 people will die from these cancers (about 19,610 men and 9,310 women) in the United States in 2017.
AFP TCR Hepatocellular Cancer Trials
This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmune's alpha fetoprotein (AFP) therapeutic candidate in hepatocellular carcinoma (HCC). Further details are available via the link below.View Clinical Trial
Please check back soon for updates.